NATURE’S SUNSHINE PRODUCTS, INC. Proceeds from Long-term Lines of Credit
NATURE’S SUNSHINE PRODUCTS, INC. (NATR) reported Proceeds from Long-term Lines of Credit of $45.01 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2023-03-16
- NATURE’S SUNSHINE PRODUCTS, INC. proceeds from long-term lines of credit for the quarter ending 2018-12-31 was $22.81M.
- NATURE’S SUNSHINE PRODUCTS, INC. proceeds from long-term lines of credit for the quarter ending 2018-09-30 was $18.00M, a 6.19% decline year-over-year.
- NATURE’S SUNSHINE PRODUCTS, INC. proceeds from long-term lines of credit for the quarter ending 2017-09-30 was $19.18M.
- NATURE’S SUNSHINE PRODUCTS, INC. proceeds from long-term lines of credit for fiscal 2022 was $45.01M.
- NATURE’S SUNSHINE PRODUCTS, INC. proceeds from long-term lines of credit for fiscal 2021 was $0.00.
- NATURE’S SUNSHINE PRODUCTS, INC. proceeds from long-term lines of credit for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- NATURE’S SUNSHINE PRODUCTS, INC. proceeds from long-term lines of credit for fiscal 2019 was $2.06M, a 96.98% decline from fiscal 2018.
| Period end | Proceeds from Long-term Lines of Credit 3 month | Proceeds from Long-term Lines of Credit 6 month | Proceeds from Long-term Lines of Credit 9 month | Proceeds from Long-term Lines of Credit 12 month |
|---|---|---|---|---|
| 2022-12-31 | $45.01M 10-K · filed 2023-03-16 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-16 | |||
| 2020-12-31 | $0.00 10-K · filed 2021-03-10 | |||
| 2019-12-31 | $2.06M 10-K · filed 2021-03-10 | |||
| 2018-12-31 | $22.81M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $40.81M derived: sum of 2 quarters · filed 2020-03-11 | $68.32M 10-K · filed 2020-03-11 | |
| 2018-09-30 | $18.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $45.51M 10-Q · filed 2018-11-08 | ||
| 2018-06-30 | $27.51M 10-Q · filed 2018-08-08 | |||
| 2017-09-30 | $19.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $19.18M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-08 | |||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-09 | |||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-06 | |||
| 2013-09-30 | $10.00M 10-Q · filed 2014-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |